The drug has consistently demonstrated OS benefit while preserving or improving quality of life across three Phase III trials in metastatic breast cancer. Updates to theNCCN Guidelines for breast cancer, released in January 2023, recommendKISQALI as the only Category 1 preferred CDK4/6 inhibitor for...
R01 CA185138 and R01 CA140657 as well as CDMRP Breast Cancer Research Program Award BC132057 and an Arizona Investigator Grant ADHS18-198847. We also acknowledge funding of the Pilot LEGACY programme by Breast Cancer Now (Breakthrough Breast Cancer) UK. L.M. is supported by Cancer Resear...
The FDA as granted a breakthrough device designation to ZetaMet, a technology designed to target and resolve metastatic bone lesions, according to a press release by Zetagen Therapeutics. ZetaMet, which was previously known as ZetaFuse, is a synthetic, small-molecule biologic technology that is...
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-relate... J Weiss,A Glode,WA Messersmith,... - 《Expert Review...
Global OncologyHER2+ Breast Cancer December 13th 2024 China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC March 4th 2022 Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer December 6th 2024 Chemothe...
Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or
Targeted therapies target specific molecules in the tumor. In luminal breast cancer, targeted therapy inhibits CDK4/6 proteins, which control growth rate and division of cells. The approval of these inhibitors was a breakthrough in the treatment of luminal breast cancer. ...
ENHERTU has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers AstraZeneca and Daiichi Sankyo’s ENHERTU®(fam-trastuzumab deruxte...
Breakthrough Therapy designation to KN026 (HER2 bispecific antibody) combined with chemotherapy for the treatment of HER2-positive gastric cancer (including gastroesophageal junction cancer). Currently, two phase III pivotal trials of KN026 are ongoing for patients with breast cancer, or gastric cancer...
Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and support cancer progression. Thus, gaining a bett...